Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: intranasal oxytocin Clear all
Completed Phase 1 Interventional

Cocaine Opioid Oxytocin Option - Limited

NCT02028533
View directory record Official record
Conditions
Opioid Use Disorder, Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Deciphering the Role of Oxytocin in Motivation: an fMRI Study

NCT01722071
View directory record Official record
Conditions
Focus of Study: Neural Correlates of Oxytocin Administration
Interventions
Placebo, Oxytocin
Drug
Lead sponsor
Tiffany Love
Other
Eligibility
20 Years to 35 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Wellness Behaviors as a Function of Oxytocin vs Placebo

NCT01929161
View directory record Official record
Conditions
Sustained Positive Emotions, Sustained Positive Behavior Change
Interventions
Oxytocin, Placebo (for oxytocin), Lovingkindness Meditation, Mindfulness Meditation
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
35 Years to 64 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 9, 2026, 3:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose Response Relationship of Oxytocin on Irritability in Youths

NCT03863288
View directory record Official record
Conditions
Irritable Mood
Interventions
Functional MRI (fMRI), Oxytocin Intranasal Spray 8 International Unit (8IU), Oxytocin intranasal spray 24 International Unit (24IU), Oxytocin intranasal spray 48 International Unit (48IU), Oxytocin intranasal spray 80 International Unit (80IU), Placebo
Procedure · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
14 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

NCT03119610
View directory record Official record
Conditions
Obesity, Sarcopenic Obesity, Sarcopenia, Aging, Sedentary Lifestyle
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Sara Espinoza
Other
Eligibility
60 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin in Hypothalamic Obesity

NCT02849743
View directory record Official record
Conditions
Craniopharyngioma, Hypothalamic Obesity
Interventions
Syntocinon, Placebo (for Syntocinon)
Drug
Lead sponsor
Shana McCormack, MD
Other
Eligibility
10 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 9, 2026, 3:33 AM EDT
Withdrawn Phase 2 Interventional

Intranasal Oxytocin and Learning in Autism

NCT02090829
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Syntocinon (synthetic oxytocin), Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

NCT01312272
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxytocin Treatment of Opioid Dependence

NCT02548728
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal
Interventions
Intranasal Oxytocin Spray, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Brief Cognitive Behavioral Conjoint Therapy for PTSD With Adjunctive Intranasal Oxytocin

NCT05207436
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Relational Problems
Interventions
Oxytocin nasal spray, Brief Cognitive-Behavioral Conjoint Therapy
Drug · Behavioral
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

NCT01254045
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
placebo, oxytocin 24IU, oxytocin 48IU
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 29 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 9, 2026, 3:33 AM EDT
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT), Placebo
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Social Cognition in Schizophrenia

NCT00884897
View directory record Official record
Conditions
Social Cognition, Social Anxiety, Emotional Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

NCT01712646
View directory record Official record
Conditions
Childhood Onset Psychotic Disorders, Schizophrenia
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children

NCT03337035
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
intranasal oxytocin, oral probiotics, oral placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 9, 2026, 3:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Methadone Oxytocin Option

NCT01728909
View directory record Official record
Conditions
Substance Abuse, Opioid Dependence, Methadone Treatment
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Terminated Phase 2Phase 3 Interventional

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

NCT03819231
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Stimulant Oxytocin Study

NCT03016598
View directory record Official record
Conditions
Stimulant Use & Co-occuring Opioid Use Disorders
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCT01614093
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 9, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

NCT01931033
View directory record Official record
Conditions
Autism Spectrum Disorders, Pervasive Developmental Disorders, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 9, 2026, 3:33 AM EDT
Not listed Phase 1 Interventional

Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence

NCT02052258
View directory record Official record
Conditions
Opiate Dependence
Interventions
Oxytocin
Drug
Lead sponsor
MacDonald, Kai, M.D.
Individual
Eligibility
18 Years and older · Male only
Timeline
Started 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 9, 2026, 3:33 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

NCT01123317
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 9, 2026, 3:33 AM EDT